HC Wainwright & Co. Reiterates Buy on Heron Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk 10 months ago
NewsPrice TargetReiterationAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Brandon Folkes reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $6 price target.
HC Wainwright & Co. analyst Brandon Folkes reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $6 price target.